Browsing: Rani

SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported positive initial data from the ongoing Phase 1 study of RT-114, an orally administered RaniPill ® Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen Co.,…